Arcturus Therapeutics Holdings Inc. - Multiplikator EV/Sales ARCT

Logo perusahaan publik arcturusrx.com (ARCT)

Arcturus Therapeutics (ARCT) combines an asset-light mRNA production model with a strong team of specialized scientists. The company's price-to-sales ratio reflects the business valuation trend, where 2618.58 represents the latest metric reading. However, global political tensions and sanctions seriously hinder the cross-border logistics of biosamples, creating risks for the development of innovative medicines.

Arcturus Therapeutics - Rasio nilai perusahaan marang pendapatan ARCT (periode 23.11.2025 - 20.11.2026)

Arcturus Therapeutics Inc - rincian analitis lan metrik utama (ARCT)

Analisis wiwitan perusahaan:Arcturus Therapeutics ARCT
Produk seri Arcturus Therapeutics Holdings Inc.

The reliability of an equity asset is determined by comparing the business's market value with its operational efficiency. This indicator aggregates capitalization and net debt, dividing them by sales volume to eliminate the impact of leverage. For Arcturus Therapeutics (ARCT), such a valuation is critical due to its dependence on RNA component imports and the complexity of patent protection. By analyzing the enterprise value-to-annual revenue multiple, an investor identifies an overvaluation of the asset against a backdrop of geopolitical risks.